Mortality rate among HIV-positive children on ART in Northwest Ethiopia: a historical cohort study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
27 Aug 2020
Historique:
received: 17 05 2019
accepted: 20 08 2020
entrez: 29 8 2020
pubmed: 29 8 2020
medline: 16 12 2020
Statut: epublish

Résumé

Though highly active antiretroviral therapy (HAART) has been available for more than a decade in Ethiopia, information regarding mortality rates of human immunodeficiency virus (HIV)-positive children after antiretroviral therapy antiretroviral therapy (ART) initiation is very scarce. Thus, this study intends to determine the predictors of mortality among HIV-positive children receiving ART in Amhara Region. A multicenter facility-based historical cohort study was conducted in 538 HIV-positive children on ART from January 2012 to February 2017. We employed a standardized data extraction tool, adapted from ART entry and follow-up forms. Descriptive analyses were summarized using the Kaplan-Meier survival curve and log rank test. Then, the Cox-proportional hazard regression model was employed to estimate the hazard of death up to five-years after ART initiation. Variables with p-values ≤0.25 in bivariable analysis were candidates to the multivariable analysis. Finally, variables with p-values < 0.05 were considered as significant variables. The cohort contributed a total follow-up time of 14,600 child-months, with an overall mortality rate of 3.2 (95% CI: 2.3, 4.3) per 100 child-years. This study also indicated that HIV-infected children presenting with opportunistic infections (OIs) (AHR: 2.5, 95% CI: 1.04, 5.9), anemia (AHR: 3.1, 95% CI: 1.4, 6.7), severe immunodeficiency (AHR: 4.4, 95% CI: 1.7, 11.7), severe stunting (AHR: 3.3, 95% CI: 1.4, 8.0), severe wasting (AHR: 3.1, 95% CI: 1.3, 7.3), and advanced disease staging (III and IV) (AHR: 3.0, 95% CI: 1.2, 7.1) were at higher risk of mortality. A higher rate of mortality was observed in our study as compared to previous Ethiopian studies. HIV-positive children presenting with anemia, OIs, severe immunodeficiency, advanced disease staging (III and IV), severe stunting, and severe wasting were at higher risk of mortality.

Sections du résumé

BACKGROUND BACKGROUND
Though highly active antiretroviral therapy (HAART) has been available for more than a decade in Ethiopia, information regarding mortality rates of human immunodeficiency virus (HIV)-positive children after antiretroviral therapy antiretroviral therapy (ART) initiation is very scarce. Thus, this study intends to determine the predictors of mortality among HIV-positive children receiving ART in Amhara Region.
METHODS METHODS
A multicenter facility-based historical cohort study was conducted in 538 HIV-positive children on ART from January 2012 to February 2017. We employed a standardized data extraction tool, adapted from ART entry and follow-up forms. Descriptive analyses were summarized using the Kaplan-Meier survival curve and log rank test. Then, the Cox-proportional hazard regression model was employed to estimate the hazard of death up to five-years after ART initiation. Variables with p-values ≤0.25 in bivariable analysis were candidates to the multivariable analysis. Finally, variables with p-values < 0.05 were considered as significant variables.
RESULTS RESULTS
The cohort contributed a total follow-up time of 14,600 child-months, with an overall mortality rate of 3.2 (95% CI: 2.3, 4.3) per 100 child-years. This study also indicated that HIV-infected children presenting with opportunistic infections (OIs) (AHR: 2.5, 95% CI: 1.04, 5.9), anemia (AHR: 3.1, 95% CI: 1.4, 6.7), severe immunodeficiency (AHR: 4.4, 95% CI: 1.7, 11.7), severe stunting (AHR: 3.3, 95% CI: 1.4, 8.0), severe wasting (AHR: 3.1, 95% CI: 1.3, 7.3), and advanced disease staging (III and IV) (AHR: 3.0, 95% CI: 1.2, 7.1) were at higher risk of mortality.
CONCLUSION CONCLUSIONS
A higher rate of mortality was observed in our study as compared to previous Ethiopian studies. HIV-positive children presenting with anemia, OIs, severe immunodeficiency, advanced disease staging (III and IV), severe stunting, and severe wasting were at higher risk of mortality.

Identifiants

pubmed: 32854692
doi: 10.1186/s12889-020-09418-6
pii: 10.1186/s12889-020-09418-6
pmc: PMC7457276
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1303

Références

Ethiop Med J. 2010 Jan;48(1):1-10
pubmed: 20607992
BMC Pediatr. 2012 Oct 08;12:161
pubmed: 23043325
AIDS Care. 2015;27(6):723-30
pubmed: 25599414
J Int Assoc Provid AIDS Care. 2015 Mar-Apr;14(2):172-9
pubmed: 24106055
Adv Med. 2018 Jun 19;2018:6409134
pubmed: 30018988
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
pubmed: 12569078
Pediatr Infect Dis J. 2014 Nov;33(11):1148-55
pubmed: 24945879
Med Mal Infect. 2017 Feb;47(1):32-37
pubmed: 27609595
BMC Pediatr. 2010 May 18;10:33
pubmed: 20482796
Arch Public Health. 2013 Jun 08;71(1):13
pubmed: 23759075
Int J Tuberc Lung Dis. 2013 Nov;17(11):1389-95
pubmed: 24125439
Pediatrics. 2012 Sep;130(3):e591-9
pubmed: 22891234
PLoS One. 2011;6(7):e22706
pubmed: 21829487
Blood. 1998 Jan 1;91(1):301-8
pubmed: 9414298
PLoS One. 2011;6(12):e29294
pubmed: 22216237
AIDS. 1999 May 28;13(8):943-50
pubmed: 10371175
J Paediatr Child Health. 2015 Feb;51(2):204-8
pubmed: 25142757
BMC Public Health. 2019 Jan 28;19(1):115
pubmed: 30691416
BMC Public Health. 2013 Nov 06;13:1047
pubmed: 24517533
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):464-70
pubmed: 16010171
J Pediatr Gastroenterol Nutr. 2013 Aug;57(2):258-64
pubmed: 23880630
Mem Inst Oswaldo Cruz. 2012 Jun;107(4):532-8
pubmed: 22666865
Indian Pediatr. 2018 Apr 15;55(4):301-305
pubmed: 29428912
SAGE Open Med. 2019 Mar 25;7:2050312119838957
pubmed: 30937168
PLoS One. 2014 Dec 08;9(12):e113095
pubmed: 25485634

Auteurs

Animut Alebel (A)

College of Health Science, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia. animut.a23@gmail.com.
Australian Centre for Public and Population Health Research, School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia. animut.a23@gmail.com.

Eshetu Haileselassie Engeda (EH)

College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Mengistu Mekonnen Kelkay (MM)

College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Pammla Petrucka (P)

College of Nursing, University of Saskatchewan, Saskatoon, Canada.
School of Life Sciences and Bioengineering, Nelson Mandela African Institute of Science and Technology, Arusha, Tanzania.

Getiye Dejenu Kibret (GD)

College of Health Science, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.
Australian Centre for Public and Population Health Research, School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia.

Fasil Wagnew (F)

College of Health Science, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.

Getnet Asmare (G)

Debre Tabor University, College of Health Sciences, Debre Tabor, Ethiopia.

Zebenay Workneh Bitew (ZW)

Department of Nursing, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.

Daniel Bekele Ketema (DB)

College of Health Science, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.

Getnet Gedif (G)

College of Health Science, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.

Belisty Temesgen (B)

Debre Markos Referral Hospital, Debre Markos, Ethiopia.

Yitbarek Tenaw Hibstie (YT)

Debre Markos Referral Hospital, Debre Markos, Ethiopia.

Mamaru Wubale Melkamu (MW)

Debre Markos Referral Hospital, Debre Markos, Ethiopia.

Setegn Eshetie (S)

College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH